A 6-year-old girl died after receiving an experimental brain-directed gene-editing therapy at Xinhua Hospital in Shanghai, prompting renewed scrutiny of how regulators oversee first-in-human personalized gene therapies. The incident has reopened debate around trial governance, patient safety monitoring, and the evidentiary expectations for early-stage gene-editing programs. The case is being treated as an ethical fault-line moment for the broader personalized gene therapy model, with investigators and oversight bodies weighing how safety signal handling should work across novel editing approaches. For the field, the development adds urgency to clinical trial safeguards in gene editing—particularly around the depth of preclinical rationale, adverse event readiness, and transparent reporting practices.